• SPX
  • $5,917.11
  • 0 %
  • $0.13
  • DJI
  • $43,408.47
  • 0.32 %
  • $139.53
  • N225
  • $38,026.17
  • -0.85 %
  • -$326.17
  • FTSE
  • $8,111.07
  • 0.32 %
  • $26.00
  • IXIC
  • $18,966.14
  • -0.11 %
  • -$21.33
AstraZeneca PLC (AZN) Stock Price, News & Analysis

AstraZeneca PLC (AZN) Stock Price, News & Analysis

Currency in USD Disclaimer

$63.19

-$0.61

(-0.96%)

Day's range
$62.88
Day's range
$63.93
50-day range
$62.75
Day's range
$79.99
  • Country: GB
  • ISIN: US0463531089
52 wk range
$60.47
Day's range
$87.68
  • CEO: Mr. Pascal Soriot D.V.M., M.B.A.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 2.65
  • Piotroski Score 6.00
  • Grade Buy
  • Symbol (AZN)
  • Company AstraZeneca PLC
  • Price $63.19
  • Changes Percentage (-0.96%)
  • Change -$0.61
  • Day Low $62.88
  • Day High $63.93
  • Year High $87.68

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

  • Last Earnings 07/25/2024
  • Ex-Dividend for 5/16 Dividend 08/09/2024
  • Dividend Payable 09/09/2024
  • Today N/A
  • Next Earnings (Estimated) 02/06/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $85.00
  • High Stock Price Target $88.00
  • Low Stock Price Target $79.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $2.03
  • Trailing P/E Ratio 39.42
  • Forward P/E Ratio 39.42
  • P/E Growth 39.42
  • Net Income $5.96 B

Income Statement

Quarterly

Annual

Latest News of AZN

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

AstraZeneca PLC Frequently Asked Questions

  • What were the earnings of AZN in the last quarter?

    In the last quarter AstraZeneca PLC earnings were on Tuesday, November, 12th. The AstraZeneca PLC maker reported $1.04 EPS for the quarter, beating analysts' consensus estimates of $1.01 by $0.03.

  • What is the AstraZeneca PLC stock price today?

    Today's price of AstraZeneca PLC is $63.19 — it has decreased by -0.96% in the past 24 hours. Watch AstraZeneca PLC stock price performance more closely on the chart.

  • Does AstraZeneca PLC release reports?

    Yes, you can track AstraZeneca PLC's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the AstraZeneca PLC stock forecast?

    Watch the AstraZeneca PLC chart and read a more detailed AstraZeneca PLC stock forecast to see what analysts suggest you do with its shares.

  • What is AstraZeneca PLC stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by AstraZeneca PLC stock ticker.

  • How to buy AstraZeneca PLC stocks?

    Like other stocks, AZN shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is AstraZeneca PLC's EBITDA?

    AstraZeneca PLC measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in AstraZeneca PLC’s financial statements.

  • What is the AstraZeneca PLC's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0.1299906136, which equates to approximately 13.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in AstraZeneca PLC stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including AstraZeneca PLC's financials relevant news, and technical analysis. AstraZeneca PLC's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for AstraZeneca PLC stock currently indicates a “sell” signal. For more insights, review AstraZeneca PLC’s technical analysis.

  • A revenue figure for AstraZeneca PLC for its last quarter?

    AstraZeneca PLC published it's last quarterly revenues at $13.57 B.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.